comparemela.com

Page 6 - Lymph Node News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Neoadjuvant pembrolizumab achieves major pathologic response in more than half of patients with resectable melanoma

In exploratory analyses of results from the SWOG S1801 trial in patients with stage III-IV resectable melanoma, researchers saw a major pathologic response in more than half of surgical specimens taken from patients who had been treated with neoadjuvant (pre-operative) pembrolizumab.

Glossary of terms

vimarsana © 2020. All Rights Reserved.